Protein kinase CK2 is a ubiquitous and pleiotropic Ser/ Thr protein kinase involved in cell growth and transformation. Here we report the identi®cation by yeast interaction trap of a CK2 interacting protein, UBC3B, which is highly homologous to the E2 ubiquitin conjugating enzyme UBC3/CDC34. UBC3B complements the yeast cdc34-2 cell cycle arrest mutant in S. cerevisiae and transfers ubiquitin to a target substrate in vitro. UBC3B is speci®cally phosphorylated by CK2 in vitro and in vivo. We mapped by deletions and site directed mutagenesis the phosphorylation site to a serine residue within the C-terminal domain in position 233 of UBC3B and in the corresponding serine residue of UBC3. Following CK2-dependent phosphorylation both UBC3B and UBC3 bind to the F-box protein b-TrCP, the substrate recognition subunit of an SCF (Skp1, Cul1, F-box) ubiquitin ligase. Furthermore, we observed that co-transfection of CK2a' together with UBC3B, but not with UBC3DC, enhances the degradation of b-catenin. Taken together these data suggest that CK2-dependent phosphorylation of UBC3 and UBC3B functions by regulating b-TrCP substrate recognition.
Introduction
Cell cycle progression is triggered by a signalling cascade which involves a series of protein phosphorylations, as well as induction and degradation of positive regulators of the cell cycle. The deregulated activation of molecules involved in this signalling might lead to uncontrolled cell cycle progression and cell transformation. Protein kinase CK2 is a ubiquitous Ser/Thr kinase (for review see Allende and Allende, 1995; Issinger, 1993; Pinna, 1990; Pinna and Meggio, 1997; Tuazon and Traugh, 1991) . Studies from several laboratories have shown a deregulated expression of this kinase in haematopoietic and solid tumours. In particular, in tumours of the prostate, kidney, colon and squamous cell carcinoma of the head and neck (Ahmed, 1994; Gapany et al., 1995; Munstermann et al., 1990; Rayan et al., 1985; Seitz et al., 1989; Stalter et al., 1994; Yenice et al., 1994) . CK2 over-expression leads to tumorigenesis in vivo and transformation of primary embryo ®broblasts together with Ras (Landesman-Bollag et al., 2001; Orlandini et al., 1998; Seldin and Leder, 1995) . CK2 holoenzyme consists of two catalytic (a and/or a') and two regulatory (b) subunits assembled as stable heterotetramers whose site speci®-city is determined by multiple acidic and/or previously phosphorylated residues, the one at position n+3 relative to the phosphoacceptor amino acid being of crucial relevance (minimum consensus S/TXXE/D/Yp/ Sp) (Meggio et al., 1994b) . Several proteins phosphorylated by CK2 are implicated in signal transduction, transcriptional activation, cell cycle progression, and cell dierentiation (Allende and Allende, 1998; Blanquet, 2000; Pinna and Meggio, 1997) .
To identify CK2 interacting proteins we performed a genetic screen in yeast. A positive clone in our screen codes for a new member of the ubiquitin conjugating enzyme family that we named UBC3B for its high similarity with the E2 ubiquitin conjugating enzyme UBC3/CDC34.
The ubiquitin-dependent proteolytic pathway plays a pivotal role in regulating the abundance of regulatory proteins involved in several cell regulatory pathways. Ubiquitin-proteasome-mediated protein degradation involves the covalent binding of the 76 amino acid ubiquitin polypeptide to substrate proteins that will be recognized by the proteasome. Ubiquitination reaction is initiated by the ubiquitin-activating enzyme (E1) which forms a thioester bond with ubiquitin, which is then transferred to a reactive cysteine residue of a ubiquitin-conjugating enzyme (E2 or UBC) (Hershko and Ciechanover, 1998; Hershko et al., 2000; Hochstrasser, 1996) . Ubiquitin is then transferred to the egroup of the reactive lysine residue of the target protein from E2 generally with the help of the ubiquitin ligase (E3) enzymes (reviewed in Jackson et al., 2000; Weissman, 2001) . E2 proteins are a family of proteins with a conserved core domain containing a cysteine residue that is the active site for the thioester bond with ubiquitin. The speci®city of the substrate recognition is achieved by the combinatorial interactions among dierent E2 and E3 factors (DeSalle and Pagano, 2001 ). In S. cerevisiae Cdc34 is required for the G1 to S transition (Goebl et al., 1988) . Many proteins involved in cell cycle progression are degraded in a cdc34-dependent manner including Sic1p, Far1, CDC6, G1 cyclins, and E2F-1 (Deshaies et al., 1995; Drury et al., 1997; Feldman et al., 1997; Henchoz et al., 1997; Marti et al., 1999; Schwob et al., 1994) . In eukaryotes the E2 CDC34 (also called UBC3), together with SCF (Skp1, Cullin, F-box protein) ligases are required for the G1 to S phase progression of the cell cycle (DeSalle and Pagano, 2001) . UBC3 participates in the G1 to S phase transition targeting the mammalian cyclin-dependent kinase inhibitor p27 for proteolysis (Pagano et al., 1995; Sutterluty et al., 1999) .
We ®rst tested in yeast whether UBC3B would behave as bona ®de CDC34 performing a complementation test using the cell cycle defective mutant cdc34-2. CK2 phosphorylates UBC3B in its C-terminal domain at a serine residue both in vitro and in vivo in transfected cells. We mapped the phosphorylation site to a serine which is conserved in UBC3B and UBC3. Importantly, the CK2-dependent phosphorylation site lies within a sequence highly similar to the consensus site for b-TrCP binding. In vitro binding experiments demonstrated that phosphorylated UBC3 and UBC3B bind speci®cally to b-TrCP. The UBC3 and UBC3B binding to b-TrCP determines an increase in the bcatenin degradation. Thus, our results suggest that CK2-dependent phosphorylation of UBC3 and UBC3B controlling their physical interaction with b-TrCP might regulate the activity of this F-box protein in its substrate recognition.
Results

CK2 interacting protein UBC3B codes for a new member of the CDC34 family
Using CK2 catalytic subunit a' in a two hybrid screen we have identi®ed among others, and in addition to several clones, coding for the b-subunit, as expected, the cDNA coding for a ubiquitin conjugating enzyme (UBC) gene highly similar to the human CDC34/UBC3 (Plon et al., 1993) . Analogous results were obtained using the other catalytic subunit CK2a. By screening mouse and human cDNA libraries we cloned both the full length mRNAs and named the new gene UBC3B.
Human and mouse UBC3B showed only one substitution while in UBC3B are present 47 substitutions with respect to UBC3. Both human and murine UBC3B contain the conserved cysteine and leucine residues which are part of the active site in the E2 enzyme (Hochstrasser, 1996) . UBC3B is identical to the rabbit cdc34 (Sun et al., 1997) suggesting that this latter is the orthologue of UBC3B rather than of CDC34/UBC3. UBC3B shows 35% identity to S. cerevisiae cdc34 over the ®rst 240 amino acids. In addition, the yeast protein contains a long C-terminal tail of 94 residues rich in aspartic and glutamic acid residues (Figure 1 ). Human UBC3 complements a mutant strain containing cdc34-2 t.s. mutant gene for growth at the restrictive temperature (Goebl et al., 1988) . To test whether UBC3B complements the cell cycle arrest cdc34-2 mutant strain we transformed this S. cerevisiae mutant strain with UBC3B under the control of GAL 1-10 promoter. As shown in Figure 2 , we observed complementation only on galactose at the non-permissive temperature therefore demonstrating that UBC3B complements the yeast cdc34 t.s. to overcome the cell cycle arrest.
Ubiquitin conjugating enzymes form thioesters with ubiquitin and transfer the ubiquitin to a target substrate. As shown in Figure 3 , in vitro UBC3B, similarly to UBC3, forms a thioester bond with ubiquitin. We also generated a mutant in the active site substituting both residues cysteine 93 and leucine 97 with serine residues. The double mutant is no longer charged with ubiquitin. Figure 1 Deduced amino acid sequence of UBC3B and alignment with other UBCs belonging to the UBC3/CDC34 family. The active site is indicated in bold. The human UBC3/ CDC34 homologue B (UBC3B) is identical at the amino acid level to its rabbit (rUBC3) homologue and shows one amino acid substitution with respect to the mouse protein (mUBC3B). Yeast protein (cdc34p) shows high identities. In addition the yeast protein contains a long acidic C-terminal domain. The sequences were aligned using the PILEUP algorithm
UBC3B is phosphorylated by CK2
The interaction trap screen suggested protein ± protein interaction between CK2 and UBC3B. We con®rmed this interaction in vitro using recombinant GST-UBC3B fusion and in vitro synthesized CK2a and a' subunits. Both subunits did bind to UBC3B (Figure 4 ). Most importantly, CK2 binding suggested that UBC3B could be a CK2 substrate. We therefore performed in vitro incubation of the recombinant GST-UBC3B with CK2 in the presence of g-[ 32 P]ATP. As shown in Figure  5a , CK2 phosphorylated UBC3B in standard conditions. CK2 phosphorylation of UBC3B appeared to be quite speci®c since the kinases CK1, cdc2, MAPK and PKA were all unable to phosphorylate UBC3B in vitro to any appreciable extent while they were able to phosphorylate their speci®c substrate in the same condition (Figure 5a , compare lanes 2 ± 5 with 6 ± 9). CK2 preferentially phosphorylates Ser/Thr residues in regions rich in acidic residues (Meggio et al., 1994b) . Based on the consensus S/T-X-X-D/E in UBC3B two putative CK2-phosphorylation sites are present: namely the serine residues 19 and 233. To test which residue(s) is the main target we generated two deletion mutants UBC3BDN20 and UBC3BDC232 which were missing one or the other serine residues. In vitro, mutant UBC3BDC232 was no longer phosphorylated by CK2 while mutant UBC3BDN20 was phosphorylated as eciently as wild type (Figure 5b ) indicating that serine 233 of UBC3B is the main CK2 target. Site directed mutagenesis of serine residue 233 demonstrated that this serine residue is phosphorylated by CK2 (Figure 5c ). Mutagenesis of the corresponding serine residue at position 231 of UBC3 showed that this is the major CK2-phosphorylation site in this protein. However, some residual CK2-dependent Figure 2 UBC3B complements a cdc34 temperature-sensitive mutant. The expression of UBC3B in yeast allows a t.s. strain to regain viability under selective conditions. SP259 cells, containing the cdc34-2 temperature sensitive mutation, were transformed with a plasmid that allowed the expression of UBC3B in the presence of galactose (A) or with the plasmid alone (B). Replica patches were then made and cells incubated for 3 days either at the permissive temperature (258C) or at the restrictive temperature (378C) in the presence of glucose (GLU) or galactose+ranose (GAL) as the sole carbon source Figure 3 Thioester bond assay: a comparison between the two members of the CDC34 family and their respective mutants. Puri®ed wild type UBC3, double mutant inactive C93S, L97S (UBC3 CL/S), UBC3B wild type, UBC3B CL/S were tested for the ability to be charged with biotinylated ubiquitin in the presence of puri®ed ubiquitin-activating-enzyme E1. Samples were analysed by immunoblotting with HRP-streptavidin. The arrowhead marks the position of the UBC3-ubiquitin thioester Figure 4 GST-pulldown assay between GST or GST-UBC3B and in vitro translated CK2a' or CK2a. Four micrograms of GST (lane 1 and 3) or GST-UBC3B (lanes 2 and 4) fusion protein were incubated with 5 ml of ([ 35 S]methionine and cysteine) in vitro translated CK2a (lanes 1 and 2) or CK2a' (lanes 3 and 4) and then bound to reduced Glutathione (GSH)-Sepharose beads. CK2a and CK2a' proteins eluted from the beads were detected by autoradiography CK2 phosphorylates UBC3 and UBC3B F Semplici et al phosphorylation can still be observed with UBC3 S231A (Figure 5c , lanes 7 and 8). This is possibly due to the phosphorylation of threonine 233 and/or serine 203 at the C-terminal domain of UBC3.
Although none of these residues display the canonical consensus for CK2 phosphorylation (Meggio et al., 1994b) , they are nevertheless located in an acidic context which could give rise to`atypical' CK2 phosphoacceptor sites. To investigate whether UBC3B was phosphorylated in vivo we performed metabolic 32 P-labelling of HeLa cells co-transfected with UBC3B or the UBC3BDC mutant with or without an expression vector for CK2a'. Equal amounts of UBC3B or the mutant were immunoprecipitated with anti-FLAG antibodies. In this assay only the w.t. UBC3B was phosphorylated ( Figure 6 ) while its deletion mutant was not. Moreover, UBC3B phosphorylation was increased by the cotransfection of CK2a' and totally abolished by the CK2 speci®c inhibitor TBB (Sarno et al., 2001 ).
CK2-dependent UBC3B phosphorylation induces its binding to b-TrCP
The F-box protein b-TrCP recruits to the ubiquitin degradation pathway proteins once they are phosphorylated in serine residues within the highly similar consensus sites DSGXXS (IkB, b-catenin, Vpu) or DSGXXXS (ATF4) (Laney and Hochstrasser, 1999; Lassot et al., 2001; Margottin et al., 1998) . As the CK2-dependent phosphorylation of UBC3B sequence DSGNEES generates a potential b-TrCP binding site, we tested direct interaction of UBC3B wild type and mutants with b-TrCP, by incubating in vitro synthesized 35 S labelled b-TrCP with GST-fusion proteins prephosphorylated by CK2a' in vitro. Both phosphorylated UBC3 and UBC3B bound b-TrCP in vitro ( Figure 7a ). No binding was observed with UBC3B and UBC3 serine mutants. To con®rm this interaction in vivo, b-TrCP expression vector was co-transfected either with UBC3B, the UBC3B C-terminal mutant, or the UBC3B mutant in which the serine residue 233 was substituted with alanine in 293 cells. UBC3B proteins were then immunoprecipitated with anti-Flag anity matrix (Sigma). b-TrCP co-immunoprecipitated with UBC3B, but not with the mutants (Figure 7b ). Thus, strongly suggesting that CK2-dependent phosphoryla- The amino acidic sequence of UBC3B contains two major serine-residues responding to the consensus CK2 phosphorylation site (S/TXXE/ D/Sp/Tp): Ser-19 and Ser-233. The deletion mutants lacking respectively the serine-residue in position 19 (UBC3BDN20) and the one in position 233 (UBC3BDC232) were tested for in vitro phosphorylation by puri®ed CK2. (c) 1 and 2 mg of recombinant wild type UBC3B and a mutant containing the serine 233 substituted with alanine (UBC3B S233A); wild type UBC3 and serine to alanine mutant were tested for in vitro phosphorylation by puri®ed CK2 Figure 6 UBC3B is phosphorylated by protein kinase CK2 in vivo. Wild type protein UBC3B expressed in eukaryotic cells is phosphorylated in vivo; co-expression of protein kinase CK2a' catalytic subunit greatly enhances UBC3B phosphorylation. UBC3B phosphorylation is completely abrogated either by expressing the mutant protein UBC3B DC232 or by adding to the culture medium the speci®c CK2 inhibitor TBB as indicated. Murine NIH3T3 ®broblasts were transiently cotransfected with pCDNA3 alone (lane 1) or with pCDNAs expressing protein FLAG-UBC3B wild type (lanes 4, 5 and 6), protein FLAG-UBC3B DC232 deletion mutant lacking the CK2 phosphorylation site Ser-233 (lanes 2 and 3), in presence (lanes 3 and 5) or absence (lanes 2 and 4) of the CK2a' catalytic subunit (CMV promoter controlled). The CK2 speci®c inhibitor TBB (lane 6) was added after transfection to the culture media to ®nal concentration of 50 mM. Transfected cells were 32 P-labelled, lysed and immunoprecipitated with a monoclonal anti-FLAG M2 antibody. Equal amounts of wild type or mutant UBC3B were loaded tion of UBC3 and UBC3B regulates their interaction with the F-box b-TrCP factor.
CK2-dependent UBC3B phosphorylation induces b-catenin degradation
Taken together the above results imply that CK2-dependent phosphorylation of UBC3 and UBC3B might be relevant for protein degradation. Interestingly, the HIV-1 Vpu protein upon phosphorylation by CK2 interacts with b-TrCP and this interaction in¯uences positively or negatively the degradation of the b-TrCP substrates CD4 and IkB (Bour et al., 2001; Margottin et al., 1998; Schubert et al., 1994) . Therefore, it is possible that, upon binding to b-TrCP, UBC3 and UBC3B could modulate the ubiquitin conjugation of b-TrCP substrate speci®city. As b-catenin is a known substrate recognized by b-TrCP we tested whether CK2-dependent phosphorylation of UBC3B could aect b-catenin stability. We therefore cotransfected 293 cells with constructs expressing bcatenin and UBC3B with or without CK2. As shown in Figure 8a , lower levels of b-catenin were observed when both CK2 and UBC3B were present. No bcatenin degradation was observed co-transfecting UBC3BDC which is not phosphorylated by CK2 and does not bind b-TrCP.
In another set of experiments we tested the levels of transcriptional activation mediated by a reporter containing multimeric responsive TCF-binding sites (TOP-CAT) or mutated TCF-binding sites (FOP-CAT) (Korinek et al., 1997) . Transfection of b-catenin induced strong TOP-CAT expression while no response was obtained with the control promoter. Signi®cant reduction of the TOP-CAT activity was observed when b-catenin was co-transfected together with CK2 and UBC3B expression vectors. On the contrary, transfection of UBC3BDC signi®cantly induced CAT activation suggesting that this mutant functions as dominant negative over the endogenous UBC3B.
Discussion
In this study we have identi®ed and characterized a novel protein that interacts with and is phosphorylated by CK2. Sequence analysis revealed that this protein codes for a new member of the E2 family of ubiquitin conjugating enzymes that is highly similar to UBC3/ CDC34. UBC3B diers from UBC3 in 47 amino acids. It retains the catalytical site for the ubiquitin charging. Both in vitro and in vivo experiments demonstrated that UBC3B is a functional member of the E2 family as, like UBC3, it is able to be charged by ubiquitin and resulted positive in the complementation test for cell cycle progression in cdc34 t.s. mutant in yeast. UBC3B is therefore a novel member of the E2 family (Haas and Siepmann, 1997; Jentsch, 1992; Matuschewski et al., 1996) . Its high similarity with UBC3 suggests that UBC3B represents another example of redundancy within the human genome and for the moment it is dicult to tell whether UBC3B has speci®c functions within the cells. UBC3 maps on chromosome 19p13.3 (Plon et al., 1993) while UBC3B with the symbol name FLJ20419 has been mapped to chromosome 9p22.1 (NCBI Annotation Project Direct Submission). In our experiments both genes behaved similarly although with some subtle dierences. For instance, while UBC3B point mutation of serine residue 233 completely abrogated CK2-dependent phosphorylation, the corresponding mutant of UBC3 showed signi®cant residual phosphorylation most likely due to some extra serine and a threonine residue present on the Cterminal domain of this protein.
Our genetic screen identi®ed UBC3B as a protein interacting with CK2. This could re¯ect that UBC3B is a substrate of CK2 or CK2 is a substrate of UBC3B. Although CK2 is a very stable protein we cannot exclude that CK2 could be an UBC3B physiological substrate. On the other hand, we have demonstrated here that UBC3B is a CK2 substrate. UBC3B is phosphorylated by CK2 both in vitro and in vivo since in HeLa cells UBC3B phosphorylation is increased by CK2 co-transfection while inhibition of its phosphor- were transfected with expression vectors for FLAG-tagged UBC3B, UBC3B C-terminal deletion and UBC3B serine to alanine substitution together with HA tagged b-TrCP construct as described. Cell extracts were immunoprecipitated for UBC3B with anti-FLAG anity gel. Co-immunoprecipitated proteins were analysed by immunoblotting using antibodies against HA CK2 phosphorylates UBC3 and UBC3B F Semplici et al ylation was obtained either with a speci®c CK2 inhibitor or by deletion of the CK2 target site in UBC3B.
The biological role of UBC3B and UBC3 phosphorylation needs further investigation. For instance, it is not possible to exclude that UBC3B phosphorylation is required for regulating its turnover. However, the level of UBC3 protein does not appear to vary with the cell cycle (Reymond et al., 2000) and we did not observe a decrease of UBC3 and UBC3B in their stability upon CK2 phosphorylation (unpublished observations). Recently it has been proposed that CK2-dependent phosphorylation of UBC3 plays a role for protein localization (Block et al., 2001) . In this respect UBC3 and UBC3B might dier considerably as we did not observe dierences in UBC3B localization upon phosphorylation (not shown). Instead, our experiments are fully consistent with the view that CK2-dependent phosphorylation of UBC3B (but also of UBC3) induces the formation of b-TrCP docking site which was observed both in vitro with GST fusion proteins and in vivo by co-immunoprecipitations. The binding of UBC3B to b-TrCP appears to have a functional role in substrate recognition as we observed a signi®cant decrease of the b-TrCP target substrate b-catenin in cells over-expressing both CK2 and UBC3B. In addition, UBC3BDC, which cannot bind b-TrCP, behaved as a dominant negative with respect to bcatenin degradation. Thus suggesting that UBC3BDC, which could still bind ROC1 and CUL1 (Wu et al., 2002) might form either inactive complexes or complexes with dierent substrate speci®city. In this light CK2-dependent phosphorylation of UBC3 and UBC3B might be important to redirect the protein degradation substrates in response to speci®c cellular conditions. Our ®nding that CK2-dependent phosphorylation leads to increased b-catenin degradation is intriguing. However, as b-TrCP recognizes several dierent substrates it is likely that its binding to UBC3 and UBC3B has an eect on several other substrates with a profound impact on cell cycle progression. As CK2 over-expression is able to contribute to cell transformation in vitro and tumour formation in transgenic animals, CK2 could exert its transforming eect, at least in part, via its regulatory activity on the proteasome-dependent protein degradation.
Materials and methods
Yeast interactor screening
The screening procedure for isolation of proteins interacting with the protein kinase CK2a' catalytic subunit was essentially performed as described (Gyuris et al., 1993) . The pEG202-CK2a' expression vector was transformed into yeast strain EGY48 bearing the pSH18-34 lacZ reporter plasmid and used for screening of a HeLa cell derived cDNA library.
Cloning of full-length UBC3B from cDNA libraries
The UBC3B cDNA fragment from the yeast vector plasmid pJG-45 was used to screen a mouse and a human ®broblast cDNA libraries (Orlandini et al., 1996) . The positive clones, inserted into the pBluescript SK vector, were sequenced on both strands. The positive clones from the human library did not contain the complete 5' end of the UBC3B cDNA, therefore we performed a 5'-rapid ampli®cation of cDNA ends (5'-RACE). The 5'-end of clone#10/UBC3B was obtained by nested RACE ± PCR using a placenta-derived cDNA template (CLONTECH). Primers used were AP1 and AP2 (CLONTECH) for the 5'-end; G301: 5'-CTGGGGA-GAAGGTGTTGGGCT-3' and G302 5'-CTCCATCCTTTT-CTGCTTCGGCC-3' for the 3'-end. In two independent experiments, the nested PCR resulted in a single cDNA fragment of identical nucleotide sequence.
Yeast complementation assay
To express UBC3B in a cdc34-2 mutant yeast strain the murine cDNA complete sequence was ampli®ed by PCR from the construct FS409 using the oligonucleotide G305: 5'-GAGAGAGAATTCGAGCTCATGGCCCAGCAGCAG-3' for the 5' and the oligonucleotide G306: 5'-GAGAGACTC-GAGGATCCTCACGACTCCTCATTTCC-3' for the 3'. Both this fragment and the expression vector Yepsec1 were digested with the enzymes BamHI and SacI and sequently ligated. For the cloning, at the 5'-end SacI had to be used necessarily to eliminate the DNA sequence encoding the Kluyveromyces lactis toxin leader peptide (Baldari et al., 1987) . The protein was expressed in the cdc34-2 mutant (temperature sensitive) S. cerevisiae strain SP259 (MATa, cdc34-2; Omns; ade2-1; trp-1; leu2-3,112; his3-11,15; ura3, can1-100) by adding galactose to the yeast culture medium, because Yepsec1 construct contains a galactose upstream activation sequence and the 5' non-translated leader of the yeast CYC1 gene, up to position 4 from the ATG translation initiation codon (Baldari et al., 1987) . The expression is conversely repressed by adding glucose to the medium. SP259 strain was a generous gift from P Plevani.
Ubiquitin thioester formation, phosphorylation assay
Puri®ed recombinant UBC3 proteins were incubated at 378C for 30 min in 30 ml of ubiquitination mix as described (Pagano et al., 1995) . In vitro phosphorylation assay were performed as described (Meggio et al., 1994a) . The incorporation of 32 P into UBC3 proteins was evaluated by subjecting samples to SDS ± PAGE, staining and autoradiography, or by direct scanning of the gel on an Instant Imager Apparatus (Canberra Packard). Protein kinases CK1 and CK2 were partially puri®ed from rat liver cytosol as described (Meggio et al., 1981) . p34/cyclinB protein kinase (star®sh) was kindly provided by Dr L Meijer (Rosco, France). PKA and MAP kinase p42 were purchased from Sigma and from Santa Cruz Biotechnology, respectively.
Metabolic
32
P labelling for in vivo phosphorylation assay NIH3T3 cells were transfected by Lipofectamine reagent according to the manufacturer's instructions (Life Technologies/Gibco BRL). Plasmid DNA (5 mg/60-mm dish) was transiently transfected for 3 h in the complete medium. Immediately post-transfection, cells were washed twice in PBS and twice in phosphate-free Dulbecco's modi®ed Eagle's medium supplemented with pyruvate. Cells were then incubated for about 16 h in the same medium containing 0.38 mCi/ml [ 32 P]orthophosphate. Where indicated, the speci®c protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) (Sarno et al., 2001) was added to the labelling medium at the ®nal 50 mM concentration. At the end of the labelling incubation cells were set on ice and washed three times with ice-cold PBS. Lysate preparation and anti-FLAG immunoprecipitation were immediately performed. The resultant cell lysates were clari®ed at 48C at 10 000 g for 10 min. Immunoprecipitations were performed by incubating cell lysate with anti-FLAG antibodies for 1 h at 48C. The samples were then incubated with protein G-Sepharose for 1 h at 48C. The resulting immunoprecipitates were washed four times with the same lysis buer and then subjected to 10% SDS ± PAGE. The gel was then dried and the presence of phosphorylated UBC3B proteins was analysed by autoradiography.
Constructs
To yield GST-UBC3B fusion protein, human UBC3B open reading frame was ampli®ed by PCR from FS410 with a 5' primer (G317) (5'-GAGAGACCATGGCCCAGCAGCA-GATGACCAGCTCGCAGA-3') and a 3' primer (G306) (5'-GAGAGACTCGAGGATCCTCACGACTCCTCATTT-CC-3'). The PRC product was digested with NcoI and XhoI and cloned into a modi®ed pGEX-4T-1 (Pharmacia) expression vector, in which an NcoI site has been inserted at the 5'-end (FG333, kindly provided by F Galvagni).
To generate GST-UBC3 fusion protein, human UBC3 open reading frame was ampli®ed by PCR from pQE30-hCDC34 (Pagano et al., 1995) with a 5'-primer (H242, 5'-GAGAGAGGATCCCCCATGGCTCGGCCGCTAGTG-3') and a 3'-primer (H243, 5'-GAGAGATCTAGATCAG-GACTCCTCCGTGCC-3'). The ampli®ed fragment was digested with BamHI and XbaI and cloned into the GSTbinding domain) of FG333.
GST-UBC3BDN20 (from L-20 to S-238), lacking the ®rst 19 amino acids at the N-terminal respect to UBC3 B wild type, was ampli®ed by PCR from FS410 with a 5'-primer containing a BamHI restriction site (G360: 5'-GAGAGAG-GATTCCTGCAGGAGGAACCGGTG-3') and a 3'-primer containing an EcoRI restriction site (G351: 5'-ATATATCTC-GAGTCACGACTCCTCATTCCC-3'). The PCR product was digested with BamHI and EcoRI and cloned into FG333.
GST-UBC3BDC232 was ampli®ed by PCR from FS410 as well, with a 5'-primer (G361: 5'-GAGAGAGAATTCAAT-CATCATCATCATAACA-3') and the 3'-primer (G348: 5'-GAGAGAGGATCCATGGCCCAGCAGCAGATG-3'). After digestion with the restriction enzymes BamHI and EcoRI, the ampli®ed fragments were cloned into the FG333.
The S233A mutant GST-UBC3B S233A was generated amplifying by PCR from FS410 with G348 as the 5'-primer and the 3'-primer (H240: 5'-GAGAGATCTAGATCACGA-CTCCTCATTCCCAGCATCATCATCATCATAACA-3'). The ampli®ed fragment was digested with the restriction enzymes EcoRI and XbaI and ligated into the vector FG333.
The GST-UBC3S231A mutant was obtained by PCR from pQE30-hCDC34 with the 5'-primer H242 containing a BamHI restriction site and the 3'-primer (H241, 5'-GAGA-GATCTAGATCAGGACTCCTCCGTGCCAGCGTCATC-CTCATCGTCCCC-3'). After digestion with BamHI and XbaI the ampli®ed product was inserted into the vector FG333.
The GST-fusion proteins were generated by culturing the transformed E. coli under isopropyl ± D-thiogalactopyranoside (IPTG)-inducing conditions (0.1 mM IPTG for 2 ± 3 h at 308C). The fusion protein and/or GST control protein was then puri®ed and thrombin-cleaved (when necessary) from the GST-binding domain moiety, using glutathione-Sepharose 4B beads according to the manufacturer's protocol (Pharmacia).
The constructs expressing the N-terminally FLAG-tagged UBC3B wild type, UBC3BDC232 and UBC3BS233A phosphorylation mutants, under the control of the CMV promoter, were made by subcloning the respective fragments from the GST-fusion constructs into a modi®ed pcDNA3.1C
CK2 phosphorylates UBC3 and UBC3B6Xhis (Invitrogen), in which the N-terminal sequence coding for six Histidine residues had been eliminated by cleavage with the restriction enzymes HindIII and KpnI, and substituted with a sequence encoding the highly immunogenic FLAG peptide (N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C), maintaining the original pCDNA3.1C polylinker sequence (kindly provided by L D'Adamio).
To generate pCDNA3-HA-b-TrCP encoding an N-terminally HA-tagged bTrCP, bTrCP(Fbw1a) was ampli®ed by PCR from a plasmid (Cenciarelli et al., 1999 ) (H325 5'-GAG-AGAGATATCGCCGCCATGTATCCTTATGATGTTCCT-GATTATGCTATGGACCCGGCCGAGGCG-3') which contains the HA epitope sequence, and the reverse primer (H327 5'-TCTCTCTCTAGATTATCTGGAGATGTAGGT-GTATGTTCG).
GST pulldown affinity assay
For UBC3B and CK2a'/a in vitro binding assay, the expression of GST and GST-UBC3B fusion protein was induced in E. coli (TG1) cells by 100 mM isopropyl-l-thio-Dgalactopyranoside for 5 ± 6 h at 308C. The cells were collected by centrifugation (5000 g, 10 min), resuspended in 50 ml of PBS-T1 (16PBS with 1% Triton X-100) and lysed by sonication. The lysate was centrifuged at 10 000 g for 10 min. The supernatant was incubated with 1 ml (50% slurry) reduced Glutathione(GSH)-Sepharose (Amersham Pharmacia). After washing the beads with cold PBS at 48C, the binding proteins were eluted at room temperature with 1 ml 10 mM reduced glutathione in 50 mM Tris-HCl (pH 8.0) for three times. The eluted proteins were dialyzed against PBS overnight at 48C.
For the in vitro binding assay between the GST-fused UBC3B protein and protein kinase CK2a and a' catalytic subunits, 4 mg of puri®ed GST or GST-UBC3B were mixed (in a 20-ml reaction) in RIPA buer with sodium deoxycholate and containing protease inhibitors (SIGMA) (100 mM Tris-HCl pH 8.0, 10 mM EDTA, 150 mM NaCl, 1% Nonidet P-40, 1% Na DOC) with 5 ml of [ 35 S]methionine and cysteine (PRO-MIX tm -Amersham Pharmacia) in vitro translated CK2a' or a (TNT Quick Coupled Transcription Translation Kit, Promega). The binding reactions were incubated at 308C for 1 h, then diluted to 0.5 ml with RIPA buer and clari®ed from insoluble precipitates by centrifugation for 10 min at 20 000 g at 48C. The clear supernatants were transferred to a new tube, added with 50 ml (50% slurry) reduced Glutathione (GSH)-Sepharose (Amersham Pharmacia) equilibrated in RIPA buer, and gently rotated on wheel at 48C for 2 h. Then the beads were washed four times at 48C with RIPA buer and resuspended in 16Laemmli buer. After boiling samples 5 min at 958C bound proteins were resolved using SDS ± PAGE and analysed by autoradiography.
TCF chloramphenicol acetyltransferase (CAT) assay
The reporter plasmids TOP-CAT and FOP-CAT (Korinek et al., 1997) were generously provided by Claudio Schneider. In brief, human transformed primary embryonic kidney 293 cells were transfected using the Polyfect Transfection Reagent (Quiagen) according to the manufacturer's instructions. The day before transfection cells were seeded 1.2610 6 per 6-cmdiameter dish. Typically a transfection experiment included 0.6 mg of reporter plasmid (TOP-CAT or FOP-CAT) and 0.1 mg of cytomegalovirus-LacZ plasmid for the transfection eciency control (Cherrington and Mocarski, 1989) . The expression plasmids were added to the reporter as indicated in the legend of Figure 8 and the total amount of transfected plasmids was held constant at 4.0 mg by the addition of empty pCDNA3 as a DNA carrier. Plasmid pCS2+ MMBCmyctag encoding myc tagged mouse b-catenin (Aberle et al., 1997) was kindly provided by Rolf Kemler. The CMVdriven expression construct for b-TrCP(DF), the F-box deleted mutant of btrCP, which acts in vivo as a dominant negative mutant, being unable to bind Skp1-Cul1 complex (Latres et al., 1999) was generously provided by Michele Pagano (New York University Medical Center, New York, USA). CAT activity was determined as previously described (Gorman et al., 1982) . Acetylated forms of chloramphenicol were quanti®ed by scanning the thin-layer chromatography plates with the Image Quant radio analytic system from Molecular Dynamics. A minimum of four independent transfection experiments were performed with independent DNA preparations. The average variation of CAT activity observed for each construct was less than 10% in dierent transfections.
b-TrCP and UBC3B co-immunoprecipitation
Human embryonic kidney 293 cells (HEK293) were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% foetal bovine serum, 100 mg/ml streptomycin, and 100 units/ml penicillin. Transfections were performed using LipofectAMINE reagent according to the manufacturer's instructions (LIFE Technologies/Gibco BRL). For co-immunoprecipitation experiments with NH2-terminally HAtagged b-TrCP protein and FLAG-tagged UBC3B protein (wild type and C-terminally truncated), HEK293 cells were seeded in 100-mm plates, transfected at about 50% con¯uency with a total amount of 12 mg DNA per plate, held constant by the addition of empty pCDNA3 expression vector, and collected 48 h post-transfection. Cells were rinsed on ice twice with cold PBS, scraped in 5 ml of cold PBS supplemented with 1 mM EDTA, the pellet deriving from three plates was lysed in 0.5 ml of Triton lysis buer containing 20 mM Tris-HCl pH 8.0, 1% Triton, 140 mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl 2 , 1 mM EDTA, (2 mg/ml) 50 mM NaF, (1.8 mg/ml) 1 mM Na 3 VO 4 , 1 mM PMSF, supplemented with protease inhibitor cocktail (Sigma). The lysis was ful®lled at 48C with gentle rotation on a wheel for half an hour. Cell debris was removed and immunoprecipitation was performed as recommended by the manufacturer's instructions (Sigma) adding to the cleared lysate (100 ml (50% suspension) of ANTI-FLAG 1 M2 Anity Gel, (Sigma) and rotating the samples on a wheel at 48C for at least 2 h. The immunoprecipitates were washed four times in the same buer of lysis, resolved by SDS ± PAGE and examined by immunoblotting experiment using anti-HA High Anity (rat monoclonal antibody, clone 3F10) (Roche) and anti-FLAG 1 M2 (Sigma).
In vitro binding
In vitro binding of puri®ed and CK2a' phosphorylated GSTfusion UBC3 proteins to in vitro translated human b-TrCP was carried out in 300 ml of binding buer (10 mM Tris-HCl pH 7.6, 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl 2 , 0.1% NP40, 10% glycerol, 500 mg/ml BSA) containing about 2 mg puri®ed and CK2a' phosphorylated GST fusion UBC3 proteins and reticulocyte lysate in which radiolabelled bTrCP was produced by in vitro transcription and translation according to the manufacturer's instructions (TNT Quick Coupled Transcription/Translation systems Promega). Glutathione-Sepharose 4B (Pharmacia) equilibrated in binding buer was added to the mix and the reactions were gently rotated on a wheel at 48C for 5 h. Then the matrix was sedimented by centrifugating at 500 g for 5 min and washed ®ve times in washing buer (10 mM Tris-HCl pH 7.6, 150 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl 2 , 0.4% NP40, 10% glycerol). The matrix was resuspended in Laemmli buer, boiled and analysed by SDS ± PAGE and autoradiography. GST fusion UBC3 proteins were phosphorylated as described (Meggio et al., 1994a) using 2 mg of recombinant CK2a' subunit (Orlandini et al., 1998) .
